Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP-miR144
- Development stage
- Preclinical
- Lead developer
- Yangzhou University
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
EP-miR144 is an engineered phage vector designed for muscle-targeted delivery of microRNA-144 (miR144). Developed by researchers at Yangzhou University, it is being investigated as a systemic anti-aging therapy. In preclinical models, EP-miR144 exerts anti-aging effects by upregulating SPARC (secreted protein acidic and rich in cysteine), an extracellular matrix-associated protein that is downregulated in skeletal muscle during aging. Administration of EP-miR144 has been shown to improve metabolic and muscle function, reduce aging biomarkers and frailty, and extend lifespan in aged mice and goat models.
Beyond the preview
Go deeper on EP-miR144.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP-miR144.